Tartrate-resistant acid phosphates 5b (TRACP 5b) as a marker of bone resorption

Clinical Laboratory

Volumn 52, Issue 9-10, 2006, Pages 499-509

  Halleen, Jussi M ^a,b   Tiitinen, Sari L ^a,c   Ylipahkala, Hannele ^a   Fagerlund, Katja M ^a   Väänänen, H Kalervo ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b Pharmatest Services Ltd   (Finland)

^c Finnish Red Cross   (Finland)

Author keywords

Antiresorptive treatment; Bone resorption marker; Osteoclast; Osteoporosis; TRACP 5b

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME 5A; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME 5B; ALENDRONIC ACID; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ESTROGEN; IBANDRONIC ACID; ISOENZYME; PAMIDRONIC ACID; RALOXIFENE; RISEDRONIC ACID; UNCLASSIFIED DRUG;

BONE TURNOVER; CELL COUNT; CIRCULATION; DENDRITIC CELL; DIAGNOSTIC VALUE; ENZYME ASSAY; ENZYME RELEASE; ENZYME SYNTHESIS; HUMAN; INFLAMMATION; INFLAMMATORY CELL; INFLAMMATORY DISEASE; INTERMETHOD COMPARISON; MACROPHAGE; METHODOLOGY; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

ACID PHOSPHATASE; BIOLOGICAL MARKERS; BONE RESORPTION; CELL COUNT; ENZYME STABILITY; HUMANS; IMMUNOASSAY; ISOENZYMES; MONITORING, PHYSIOLOGIC; OSTEOCLASTS; PROTEIN ISOFORMS;

EID: 33750452295     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Hayman AR, Jones SJ, Boyde A et al. Mice lacking tartrate-resistant acid phosphatase (Acp 5) have disrupted endochondral ossification and mild osteopetrosis. Development 1996; 122: 3151-62.
2. Angel NZ, Walsh N, Forwood MR, Ostrowski MC, Cassady AI, Hume DA. Transgenic mice overexpressing tartrate-resistant acid phosphatase exhibit an increased rate of bone turnover. J Bone Miner Res 2000; 15: 103-110.
3. Minkin C. Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int 1982; 34: 285-90.
4. Efstratiadis T, Moss DW. Tartrate-resistant acid phosphatase in human alveolar macrophages. Enzyme 1985; 34: 140-3.
5. Hayman AR, Macary P, Lehner PJ, Cox TM. Tartrate-resistant acid phosphatase (Acp 5): identification in diverse human tissues and dendritic cells. J Histochem Cytochem 2001; 49: 675-84.
6. Hayman AR, Dryden AJ, Chambers TJ, Warburton MJ. Tartrate-resistant acid phosphatase from human osteoclastomas is translated as a single polypeptide. Biochem J 1991; 277: 631-4.
7. Schlosnagle DC, Bazer FW, Tsibris JC, Roberts RM. An iron-containing phosphatase induced by progesterone in the uterine fluids of pigs. J Biol Chem 1974; 249: 7574-9.
8. Davis JC, Averill BA. Evidence for a spin-coupled binuclear iron unit at the active site of the purple acid phosphatase from beef spleen. Proc Natl Acad Sci USA 1982; 79: 4623-7.
9. Lord DK, Cross NC, Bevilacqua MA et al. Type 5 acid phosphatase. Sequence, expression and chromosomal localization of a differentiation-associated protein of the human macrophage. Eur J Biochem 1990; 189: 287-93.
10. Orlando JL, Zirino T, Quirk BJ, Averill BA. Purification and properties of the native form of the purple acid phosphatase from bovine spleen. Biochemistry 1993; 32: 8120-9.
11. Ljusberg J, Ek-Rylander B, Andersson G. Tartrate-resistant purple acid phosphatase is synthesized as a latent proenzyme and activated by cysteine proteinases. Biochem J 1999; 343: 63-9.
12. Funhoff EG, Klaassen CH, Samyn B, Van Beeumen J, Averill BA. The highly exposed loop region in mammalian purple acid phosphatase controls the catalytic activity. Chembiochem 2001; 2: 355-63.
13. Baumbach GA, Saunders PT, Hazer FW, Roberts RM. Uteroferrin has N-asparagine-linked high-mannose-type oligosaccharides that contain mannose 6-phosphate. Proc Natl Acad Sci USA 1985; 81: 2985-9.
14. Wang Y, Norgard M, Andersson G. N-glycosylation influences the latency and catalytic properties of mammalian purple acid phosphatase. Arch Biochem Biophys 2005; 435: 147-56.
15. Kaija H, Alatalo SL, Halleen JM et al. Phosphatase and oxygen radical-generating activities of mammalian purple acid phosphatase are functionally independent. Biochem Biophys Res Commun 2002; 292: 128-32.
16. Janckila AJ, Woodford TA, Lam KW, Li CY, Yam LT. Protein-tyrosine phosphatase activity of hairy cell tartrate-resistant acid phosphatase. Leukemia 1992; 6:199-203.
17. Andersson G, Lindunger A, Ek-Rylander B. Isolation and characterization of skeletal acid ATPase - a new osteoclast marker? Connect Tissue Res 1989; 20: 151-8.
18. Halleen JM, Kaija H, Stepan JJ, Vihko P, Väänänen HK. Studies on the protein tyrosine phosphatase activity of tartrate-resistant acid phosphatase. Arch Biochem Biophys 1998; 352: 97-102.
19. Ek-Rylander B, Flores M, Wendel M, Heinegard D, Andersson G. Dephosphorylation of osteopontin and bone sialoprotein by osteoclastic tartrate-resistant acid phosphatase. Modulation of osteoclast adhesion in vitro. J Biol Chem 1994; 269: 14853-6.
20. Mitic N, Valizadeh M, Leung EWW et al. Human tartrate-resistant acid phosphatase becomes an effective ATPase upon proteolytic activation. Arch Biochem Biophys 2005; 439: 154-64.
21. Sibille JC, Doi K, Aisen P. Hydroxyl radical formation and iron-binding proteins. Stimulation by the purple acid phosphatases. J Biol Chem 1987; 262: 59-62.
22. Hayman AR, Cox TM. Purple acid phosphatase of the human macrophage and osteoclast. Characterization, molecular properties, and crystallization of the recombinant di-iron-oxo protein secreted by baculovirus-infected insect cells. J Biol Chem 1994; 269: 1294-300.
23. Halleen JM, Räisänen S, Salo JJ et al. Intracellular fragmentation of bone resorption products by reactive oxygen species generated by osteoclastic tartrate-resistant acid phosphatase. J Biol Chem 1999; 274: 22907-10.
24. Vääräniemi J, Halleen JM, Kaarlonen K et al. Intracellular machinery for matrix degradation in bone-resorbing osteoclasts. J Bone Miner Res 2004; 19: 1432-40.
25. Räisänen SR, Halleen J, Parikka V, Väänänen HK. Tartrate-resistant acid phosphatase facilitates hydroxyl radical formation and colocalizes with phagocytosed Staphylococcus aureus in alveolar macrophages. Biochem Biophys Res Commun 2001; 288: 142-50.
26. Bune AJ, Hayman AR, Evans MJ, Cox TM. Mice lacking tartrate-resistant acid phosphatase (Acp 5) have disordered macrophage inflammatory responses and reduced clearance of the pathogen, Staphylococcus aureus. Immunology 2001; 102: 103-13.
27. Räisänen SR, Alatalo SL, Ylipahkala H et al. Macrophages overexpressing tartrate-resistant acid phosphatase show altered profile of free radical production and enhanced capacity of bacterial killing. Biochem Biophys Res Commun 2005; 331: 120-6.
28. Buhi WC, Ducsay CA, Hazer FW, Roberts RM. Iron transfer between the purple phosphatase uteroferrin and transferrin and its possible role in iron metabolism of the fetal pig. J Biol Chem 1982; 257: 1712-23.
29. Sheu TJ, Schwarz EM, Martinez DA et al. A phage display technique identifies a novel regulator of cell differentiation. J Biol Chem 2003; 278: 438-43.
30. Perez-Amodio S, Vogels IM, Schoenmaker T et al. Endogenous expression and endocytosis of tartrate-resistant acid phosphatase (TRACP) by osteoblast-like cells. Bone 2005; 36: 1065-77.
31. Li CY, Yam LT, Lam KW. Acid phosphatase isoenzyme in human leukocytes in normal and pathologic conditions. J Histochem Cytochem 1970; 18: 473-81.
32. Lam WK, Eastlund DT, Li CY, Yam LT. Biochemical properties of tartrate-resistant acid phosphatase in serum of adults and children. Clin Chem 1978; 24: 1105-8.
33. Lam KW, Li CY, Yam LT, Desnick RJ. Comparison of the tartrate-resistant acid phosphatase in Gaucher's disease and leukemic reticuloendotheliosis. Clin Biochem 1981; 14: 177-81.
34. Janckila AJ, Parthasarathy RN, Parthasarathy LK, Seelan RS, Yam LT. Stable expression of human tartrate-resistant acid phosphatase isoforms by CHO cells. Clin Chim Acta 2002; 326: 113-22.
35. Janckila AJ, Parthasarathy RN, Parthasarathy LK et al. Properties and expression of human tartrate-resistant acid phosphatase isoform 5a by monocyte-derived cells. J Leukoc Biol 2005; 77: 209-18.
36. Stepan JJ, Silinkova-Malkova E, Havranek T et al. Relationship of plasma tartrate resistant acid phosphatase to the bone isoenzyme of serum alkaline phosphatase in hyperparathyroidism. Clin Chim Acta 1983; 133: 189-200.
37. Schiele F, Artur Y, Floc'h AY, Siest G. Total, tartrate-resistant, and tartrate-inhibited acid phosphatases in serum: biological variations and reference limits. Clin Chem 1988; 34: 685-90.
38. Nakanishi M, Yoh K, Miura T, Ohasi T, Rai SK, Uchida K. Development of a kinetic assay for band 5b tartrate-resistant acid phosphatase activity in serum. Clin Chem 2000; 46: 469-73.
39. Rico H, Villa LF. Serum tartrate-resistant acid phosphatase (TRAP) as a biochemical marker of bone remodeling. Calcif Tissue Int 1993; 52: 149-50.
40. Lam KW, Siemens M, Sun T, Li CY, Yam LT. Enzyme immunoassay for tartrate-resistant acid phosphatase. Clin Chem 1982; 28: 467-70.
41. Echetebu ZO, Cox TM, Moss DW. Antibodies to porcine uteroferrin used in measurement of human tartrate-resistant acid phosphatase. Clin Chem 1987; 33: 1832-6.
42. Nakasato YR, Janckila AJ, Halleen JM, Väänänen HK, Walton SP, Yam LT. Clinical significance of immunoassays for type-5 tartrate-resistant acid phosphatase. Clin Chem 1999; 45: 2150-7.
43. Miyazaki S, Igarashi M, Nagata A, Tominaga Y, Onodera K, Komoda T. Development of immunoassays for type-5 tartrate-resistant acid phosphatase in human serum. Clin Chim Acta 2003; 329: 109-15.
44. Kraenzlin ME, Lau KH, Liang L et al. Development of an immunoassay for human serum osteoclastic tartrate-resistant acid phosphatase. J Clin Endocrinol Metab 1990; 71: 442-51.
45. Cheung CK, Panesar NS, Haines C, Masarei J, Swaminathan R. Immunoassay of a tartrate-resistant acid phosphatase in serum. Clin Chem 1995; 41:679-86.
46. Halleen J, Hentunen TA, Hellman J, Väänänen HK. Tartrate-resistant acid phosphatase from human bone: purification and development of an immunoassay. J Bone Miner Res 1996; 11: 1444-52.
47. Chamberlain P, Compston J, Cox TM et al. Generation and characterization of monoclonal antibodies to human type-5 tartrate-resistant acid phosphatase: development of a specific immunoassay of the isoenzyme in serum. Clin Chem 1995; 41:1495-9.
48. Halleen JM, Hentunen TA, Karp M, Käkönen SM, Pettersson K, Väänänen HK. Characterization of serum tartrate-resistant acid phosphatase and development of a direct two-site immunoassay. J Bone Miner Res 1998; 13: 683-7.
49. Saunders PT, Renegar RH, Raub TJ et al. The carbohydrate structure of porcine uteroferrin and the role of the high mannose chains in promoting uptake by the reticuloendothelial cells of the fetal liver. J Biol Chem 1985; 260: 3658-65.
50. Janckila AJ, Takahashi K, Sun SZ, Yam LT. Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity. Clin Chem 2001; 47: 74-80.
51. Janckila AJ, Simons RM, Yam LT. Alternative immunoassay for tartrate-resistant acid phosphatase isoform 5b using the fluorogenic substrate naphthol ASBI-phosphate and heparin. Clin Chim Acta 2004; 347: 157-67.
52. Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Väänänen HK. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 2000; 15: 1337-45.
53. Lau KH, Onishi T, Wergedal JE, Singer FR, Baylink DJ. Characterization and assay of tartrate-resistant acid phosphatase activity in serum: potential use to assess bone resorption. Clin Chem 1987; 33: 458-62.
54. Scarnecchia L, Minisola S, Pacitti MT et al. Clinical usefulness of serum tartrate-resistant acid phosphatase activity determination to evaluate bone turnover. Scand J Clin Lab Invest 1991; 51: 517-24.
55. Halleen JM, Wahlberg L, Saloranta P and Rasi S. Stability of tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) in human serum samples. J Bone Miner Res 2005; 20 (Suppl 1): Abstract SU162.
56. Väänänen HK, Zhao H, Mulari M, Halleen JM. The cell biology of osteoclast function. J Cell Sci 2000; 113: 377-81.
57. Nesbitt SA, Horton MA. Trafficking of matrix collagens through bone-resorbing osteoclasts. Science 1997; 276: 266-9.
58. Salo J, Lehenkari P, Mulari M, Metsikkö K, Väänänen HK. Removal of osteoclast bone resorption products by transcytosis. Science 1997; 276: 270-3.
59. Ljusberg J, Wang Y, Lang P et al. Proteolytic excision of a repressive loop domain in tartrate-resistant acid phosphatase by cathepsin K in osteoclasts. J Biol Chem 2005; 280: 28370-81.
60. Salo J, Metsikkö K, Palokangas H, Lehenkari P, Väänänen HK. Bone-resorbing osteoclasts reveal a dynamic division of basal plasma membrane into two different domains. J Cell Sci 1996; 109: 301-7.
61. Alatalo SL, Halleen JM, Hentunen TA, Mönkkönen J, Väänänen HK. Rapid screening method for osteoclast differentiation in vitro that measures tartrate-resistant acid phosphatase 5b activity secreted into the culture medium. Clin Chem 2000; 46:1751-4.
62. Chu P, Chao TY, Lin YF, Janckila AJ, Yam LT. Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis. Am J Kidney Dis 2003; 41: 1052-9.
63. Alatalo SL, Penq Z, Janckila AJ et al. A novel immunoassay for the determination of tartrate-resistant acid phosphatase 5b from rat serum. J Bone Miner Res 2003a; 18: 134-9.
64. Alatalo SL, Ivaska KK, Waguespack SG, Econs MJ, Väänänen HK, Halleen JM. Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis). Clin Chem 2004; 50: 883-90.
65. Alatalo SL, Ivaska KK, Peng Z, Halleen JM, Marks SC Jr., Väänänen HK. Serum tartrate-resistant acid phosphatase 5b and osteocalcin in naturally occurring osteopetrotic rats. J Bone Miner Res 2003b; 18(Suppl. 2): Abstract SA095.
66. Ylipahkala H, Rissanen J, Väänänen HK, Halleen JM. Tartrate-resistant acid phosphatase 5b is a marker of osteoclast number in human osteoclast cultures. J Bone Miner Res 2005; 20 (Suppl 1): Abstract SU303.
67. Halleen JM, Alatalo SL, Janckila AJ, Woitge HW, Seibel MJ, Väänänen HK. Serum Tartrate-resistant acid phosphatase is a specific and sensitive marker of bone resorption. Clin Chem 2001; 47: 597-600.
68. Halleen JM, Ylipahkala H, Alatalo SL et al. Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density. Calcif Tissue Int 2002; 71: 20-5.
69. Rosenbrock H, Seifert-Klauss V, Kaspar S, Busch R, Luppa PB. Changes of biochemical bone markers during the menopausal transition. Clin Chem Lab Med 2002; 40: 143-51.
70. Martinetti A, Seregni E, Ripamonti C et al. Serum levels of tartrate-resistant acid phosphatase-5b in breast cancer patients treated with pamidronate. Int J Biol Markers 2002; 17: 253-8.
71. Capeller B, Caffier H, Sutterlin MW, Dietl J. Evaluation of tartrate-resistant acid phosphatase (TRAP) 5b as serum marker of bone metastases in human breast cancer. Anticancer Res 2003; 23: 1011-5.
72. Koizumi M, Takahashi S, Ogata E. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis. Anticancer Res 2003a; 23: 4095-9.
73. Koizumi M, Takahashi S, Ogata E. Bone metabolic markers in bisphosphonate therapy for skeletal metastases in patients with breast cancer. Breast Cancer 2003b; 10: 21-7.
74. Mose S, Menzel C, Kurth AA et al. Tartrate-resistant acid phosphatase as serum marker of bone metabolism in cancer patients. Anticancer Res 2003; 23: 2783-8.
75. Chao TY, Ho CL, Lee SH, Chen MM, Janckila A, Yam LT. Tartrate-resistant acid phosphatase 5b as a serum marker of bone metastasis in breast cancer patients. J Biomed Sci 2004; 11: 511-6.
76. Jung K, Lein M, Stephan C et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 2004; 111: 783-91.
77. Lyubimova NV, Pashkov MV, Tyulyandin SA, Goldberg VE, Kushlinskii NE. Tartrate-resistant acid phosphatase as a marker of bone metastases in patients with breast cancer and prostate cancer. Bull Exp Biol Med 2004; 138: 77-9.
78. Salminen E, Ala-Houhala M, Korpela J et al. Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer. Acta Oncol 2005; 44: 742-7.
79. Takahashi K, Janckila AJ, Sun SZ, Lederer ED, Ray PC, Yam LT. Electrophoretic study of tartrate-resistant acid phosphatase isoforms in endstage renal disease and rheumatoid arthritis. Clin Chim Acta 2000; 301: 147-58.
80. Albertini B, Casez JP, Cheneval JP, Wauters JP, Jaeger PH. Low levels of 25-hydroxy-vitamin D3 (25OHD) and high serum tartrate resistant acid phosphatase 5b (TRAP 5b) activity in hemodialysis patients: relationship to secondary hyperparathyroidism. J Am Soc Nephrol 2002; 13: 571A-2A.
81. Chu P, Chao TY, Lin YF, Janckila AJ, Yam LT. Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis. Am J Kidney Dis 2003; 41: 1052-9.
82. Reichel H, Esser A, Roth HJ, Schmidt-Gayk H. Influence of PTH assay methodology on differential diagnosis of renal bone disease. Nephrol Dial Transplant 2003; 18: 759-68.
83. Avbersek-Luznik I, Balon BP, Rus I, Marc J. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? Nephrol Dial Transplant 2005; 20: 566-70.
84. Terpos E, de la Fuente J, Szydlo R et al. Tartrate-resistant acid phosphatase isoform 5b; a novel serum marker for monitoring bone disease in multiple myeloma. Int J Cancer 2003a; 106: 455-7.
85. Terpos E, Samarkos M, Meletis C et al. Unusual association between increased bone resorption and presence of paroxysmal nocturnal hemoglobinuria phenotype in multiple myeloma. Int J Hematol 2003b; 7: 344-8.
86. Terpos E, Viniou N, de la Fuente J et al. Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma. Eur J Haematol 2003c; 70: 34-42.
87. Terpos E, Politou M, Szydlo R et al. Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/ osteoprotegerin ratio in patients with multiple myeloma. Leukemia 2004; 18: 1420-6.
88. Gerdhem P, Ivaska KK, Alatalo SL et al. Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 2004; 19: 386-93.
89. Voskaridou E, Terpos E, Spina G et al. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br J Haematol 2003; 1234: 730-7.
90. Hannon RA, Clowes JA, Eagleton AC, Al Hadari AA, Eastell R, Blumsohn A. Clinical performance of immunoreactive tartrate resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone 2004; 34: 187-94.
91. Hansdottir H, Franzson L, Prestwood K, Sigurdsson G. The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities. J Am Geriatr Soc 2004; 52: 779-83.
92. Nenonen A, Cheng S, Ivaska KK et al. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 2005; 20: 1804-12.
93. Tähtelä R, Seppänen J, Laitinen K, Katajamäki A, Risteli J, Välimäki MJ. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide. Osteoporosis Int 2005; 16: 1109-16.
94. Välimäki MJ, Tähtelä R. Serum tartrate-resistant acid phosphatase 5b or amino-terminal propeptide of type I procollagen for monitoring bisphosphonate therapy in postmenopausal osteoporosis? Clin Chem 2005; 51: 2382-5.
95. Rissanen JP, Reponen JJ, Hirsinummi R, Ravanti L, Kallio PJ, Halleen JM. The ratio of osteoclast activity/osteoclast number (CTX/TRACP 5b) is a useful parameter in rat orchidectomy model. J Bone Miner Res 2005; 20 (Suppl 1): Abstract SU161.
96. Fagerlund KM, Janckila AJ, Ylipahkala H et al. Comparison of the clinical performance of six different serum tartrate-resistant acid phosphatase assays for monitoring alendronate treatment J Bone Miner Res 2005; 20 (Suppl 1): Abstract SU147.
97. Ju HS, Leung S, Brown B et al. Comparison of analytical performance and biological variability of three bone resorption assays. Clin Chem 1997; 43: 1570-6.
98. Woitge HW, Pecherstorfer M, Li Y et al. Novel serum markers of bone resorption: Clinical assessment and comparison with established urinary indices. J Bone Miner Res 1999; 14: 792-801.
99. Clowes JA, Hannon RA, Yap TS, Hoyle NR, Blumsohn A, Eastell R. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 2002; 30: 886-90.
100. Henriksen DB, Alexandersen P, Hartmann B, Adrian C, Byrjalsen I, Holst JJ. GLP-2 administration attenuates nocturnal bone resorption in postmenopausal women: A 14-day study. J Bone Miner Res 2005; 20 (Suppl 1): Abstract 1225.